CN109562114A - 用于治疗实体瘤的给药方案 - Google Patents

用于治疗实体瘤的给药方案 Download PDF

Info

Publication number
CN109562114A
CN109562114A CN201780052146.2A CN201780052146A CN109562114A CN 109562114 A CN109562114 A CN 109562114A CN 201780052146 A CN201780052146 A CN 201780052146A CN 109562114 A CN109562114 A CN 109562114A
Authority
CN
China
Prior art keywords
oxo
cancer
doses
week
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780052146.2A
Other languages
English (en)
Chinese (zh)
Inventor
K.A.本哈吉
E.S.M.袁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to CN202310314953.4A priority Critical patent/CN116473978A/zh
Publication of CN109562114A publication Critical patent/CN109562114A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201780052146.2A 2016-08-31 2017-08-24 用于治疗实体瘤的给药方案 Pending CN109562114A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310314953.4A CN116473978A (zh) 2016-08-31 2017-08-24 用于治疗实体瘤的给药方案

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662381911P 2016-08-31 2016-08-31
US62/381911 2016-08-31
PCT/US2017/048308 WO2018044662A1 (en) 2016-08-31 2017-08-24 Dosage regimen for treatment of solid tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310314953.4A Division CN116473978A (zh) 2016-08-31 2017-08-24 用于治疗实体瘤的给药方案

Publications (1)

Publication Number Publication Date
CN109562114A true CN109562114A (zh) 2019-04-02

Family

ID=59772787

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780052146.2A Pending CN109562114A (zh) 2016-08-31 2017-08-24 用于治疗实体瘤的给药方案
CN202310314953.4A Pending CN116473978A (zh) 2016-08-31 2017-08-24 用于治疗实体瘤的给药方案

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310314953.4A Pending CN116473978A (zh) 2016-08-31 2017-08-24 用于治疗实体瘤的给药方案

Country Status (14)

Country Link
US (1) US20190209581A1 (https=)
EP (1) EP3506905B1 (https=)
JP (2) JP2019526632A (https=)
KR (1) KR102512899B1 (https=)
CN (2) CN109562114A (https=)
AU (1) AU2017321011B2 (https=)
BR (1) BR112019002461A2 (https=)
CA (1) CA3035616A1 (https=)
ES (1) ES2977556T3 (https=)
IL (2) IL264924B2 (https=)
MA (1) MA46086A (https=)
MX (1) MX387397B (https=)
SG (2) SG11201901325UA (https=)
WO (1) WO2018044662A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
JP6911047B2 (ja) 2016-04-12 2021-07-28 イーライ リリー アンド カンパニー がんの処置のための、Ｎｏｔｃｈ阻害剤およびＣＤＫ４／６阻害剤の併用療法
EP3442528B1 (en) 2016-04-12 2021-05-26 Eli Lilly and Company Combination therapy with notch and pi3k/mtor inhibitors for use in treating ovarian cancer
JP7194022B2 (ja) 2016-05-20 2022-12-21 イーライ リリー アンド カンパニー Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法
EP3525796A1 (en) 2016-10-12 2019-08-21 Eli Lilly and Company Targeted treatment of mature t-cell lymphoma
MX2019009552A (es) 2017-02-17 2019-10-02 Hutchinson Fred Cancer Res Terapias de combinacion para el tratamiento de canceres relacionados con el antigeno de maduracion de celulas b (bcma) y trastornos autoinmunitarios.
MX2020004568A (es) 2017-11-06 2020-10-05 Juno Therapeutics Inc Combinación de una terapia celular y un inhibidor de gamma secretasa.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008112249A1 (en) * 2007-03-13 2008-09-18 Trustees Of Columbia University In The City Of New York Synergistic interaction of notch-1 inhibitors with glucocorticoids
WO2013016081A1 (en) * 2011-07-27 2013-01-31 Eli Lilly And Company Notch pathway signaling inhibitor compound

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US46206A (en) 1865-02-07 Improved vessel for holding petroleum
US20090149433A1 (en) * 2007-11-13 2009-06-11 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
CN106488775A (zh) * 2014-07-11 2017-03-08 基因泰克公司 Notch途径抑制
TWI609687B (zh) * 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008112249A1 (en) * 2007-03-13 2008-09-18 Trustees Of Columbia University In The City Of New York Synergistic interaction of notch-1 inhibitors with glucocorticoids
WO2013016081A1 (en) * 2011-07-27 2013-01-31 Eli Lilly And Company Notch pathway signaling inhibitor compound

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHRISTOPHE MASSARD 等: "Fisrt-in-human study of LY3039478,a Notch signaling inhibitor in advanced or metastatic cancer", 《JOURNAL OF CLINICAL ONCOLOGY》 *
EUNICE YUEN 等: "Abstract CT048:Population pharmacokinetics and pharmacodynamics for an oral Notch inhibitor,LY3039478,in the first-in-man study", 《CANCER RESEARCH》 *

Also Published As

Publication number Publication date
EP3506905B1 (en) 2024-03-20
EP3506905A1 (en) 2019-07-10
MX387397B (es) 2025-03-18
BR112019002461A2 (pt) 2019-05-14
KR102512899B1 (ko) 2023-03-23
SG11201901325UA (en) 2019-03-28
AU2017321011B2 (en) 2023-08-03
CA3035616A1 (en) 2018-03-08
IL264924B2 (en) 2024-01-01
IL264924A (https=) 2019-04-30
ES2977556T3 (es) 2024-08-26
MX2019002066A (es) 2019-06-03
MA46086A (fr) 2019-07-10
SG10202107832UA (en) 2021-09-29
WO2018044662A1 (en) 2018-03-08
JP2019526632A (ja) 2019-09-19
IL264924B1 (en) 2023-09-01
CN116473978A (zh) 2023-07-25
US20190209581A1 (en) 2019-07-11
JP2023052108A (ja) 2023-04-11
AU2017321011A1 (en) 2019-02-21
KR20190042591A (ko) 2019-04-24
IL305136A (en) 2023-10-01

Similar Documents

Publication Publication Date Title
CN109562114A (zh) 用于治疗实体瘤的给药方案
Ajani et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology
Wen et al. First-in-human phase I study to evaluate the brain-penetrant PI3K/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma
Martínez-Ricarte et al. Molecular diagnosis of diffuse gliomas through sequencing of cell-free circulating tumor DNA from cerebrospinal fluid
Sanchez-Vega et al. EGFR and MET amplifications determine response to HER2 inhibition in ERBB2-amplified esophagogastric cancer
Mileshkin et al. Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non–small cell lung cancer treated with erlotinib
Hall et al. A phase I study of pegylated arginine deiminase (pegargiminase), cisplatin, and pemetrexed in argininosuccinate synthetase 1-deficient recurrent high-grade glioma
Lv et al. Value of 18F–FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients
Dolly et al. Phase I study of apitolisib (GDC-0980), dual phosphatidylinositol-3-kinase and mammalian target of rapamycin kinase inhibitor, in patients with advanced solid tumors
Desai et al. Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors
Nicolas et al. Oral drug absorption in pediatrics: the intestinal wall, its developmental changes and current tools for predictions
Bensch et al. 89Zr-lumretuzumab PET imaging before and during HER3 antibody lumretuzumab treatment in patients with solid tumors
Cullinane et al. An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development
Bausch et al. Plectin-1 as a novel biomarker for pancreatic cancer
Hillestad et al. MRI distinguishes tumor hypoxia levels of different prognostic and biological significance in cervical cancer
Kim et al. Impact of emergent circulating tumor DNA RAS mutation in panitumumab-treated chemoresistant metastatic colorectal cancer
Nishida et al. Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene
Wuest et al. Molecular imaging of GLUT1 and GLUT5 in breast cancer: a multitracer positron emission tomography imaging study in mice
Ligon et al. A phase II trial of guadecitabine in children and adults with SDH-deficient GIST, pheochromocytoma, paraganglioma, and HLRCC-associated renal cell carcinoma
Grellety et al. Enhancing abiraterone acetate efficacy in androgen receptor–positive triple-negative breast cancer: Chk1 as a potential target
Coriat et al. Pharmacokinetics and safety of DTS-108, a human oligopeptide bound to SN-38 with an esterase-sensitive cross-linker in patients with advanced malignancies: a Phase I study
Casey et al. Fumarate metabolic signature for the detection of reed syndrome in humans
Zhao et al. CUB domain-containing protein 1 (CDCP1) is a target for radioligand therapy in castration-resistant prostate cancer, including PSMA null disease
US20130237546A1 (en) Use of melanoma inhibitory activity (mia) protein as an early indicator for therapeutic response in melanoma
US20240197928A1 (en) Sodium-dependent glucose transporter 2 as a diagnostic and therapeutic target for pre-malignant lesions

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination